Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...

Pharmaceutical company Eli Lilly (LLY) has been raking it in lately thanks to its two flagship products: Mounjaro and Zepbound. These two have ...

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Indian drugmakers are hoping that bilateral discussions between the country and the United States will help them steer clear ...

Eli Lilly 's blockbuster weight loss drugs, and questions about its valuation. Then, Ricky continues his conversation with ...

The S&P 500 and Nasdaq showed bullish behavior, with the Dow Jones leading YTD gains at 4.7%, despite weak retail sales data.

The National Women’s Hall of Fame will sponsor a special screening of the film “Lilly,” a new film based on the life of 2011 Hall of Fame ...

Below are some additional issues of concern regarding Elanco and animal health. — In 2020, Elanco Animal Health completed its acquisition of Bayer’s animal health division. Bayer probably needed to ...

Mike Czapar-- Senior Vice President, Investor Relations Good morning. Thank you for joining us for Eli Lilly and Company's Q4 2024 earnings call. I'm Mike Czapar, senior vice president of investor ...

(Reuters) -Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.